Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
Faustini S, Shields A, Banham G, Wall N, Al-Taei S, Tanner C, Ahmed Z, Efstathiou E, Townsend N, Goodall M, Plant T, Perez-Toledo M, Jasiulewicz A, Price R, McLaughlin J, Farnan J, Moore J, Robertson L, Nesbit A, Curry G, Black A, Cunningham A, Harper L, Moore T, Drayson M, Richter A. Faustini S, et al. Among authors: efstathiou e. J Infect. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2022.01.002. Epub 2022 Jan 10. J Infect. 2022. PMID: 35016901 Free PMC article. No abstract available.
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study.
Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, Workman S, Moreira F, Verma N, Wagg H, Heritage G, Campton N, Stamataki Z, Klenerman P, Thaventhiran JED, Goddard S, Johnston S, Huissoon A, Bethune C, Elcombe S, Lowe DM, Patel SY, Savic S, Burns SO, Richter AG; COV-AD consortium. Shields AM, et al. J Clin Immunol. 2022 Jul;42(5):923-934. doi: 10.1007/s10875-022-01231-7. Epub 2022 Apr 14. J Clin Immunol. 2022. PMID: 35420363 Free PMC article.
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.
Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, Workman S, Moreira F, Verma N, Wagg H, Heritage G, Campton N, Stamataki Z, Drayson MT, Klenerman P, Thaventhiran JED, Elkhalifa S, Goddard S, Johnston S, Huissoon A, Bethune C, Elcombe S, Lowe DM, Patel SY, Savic S, Richter AG, Burns SO; COV-AD consortium. Shields AM, et al. Front Immunol. 2022 Jun 2;13:912571. doi: 10.3389/fimmu.2022.912571. eCollection 2022. Front Immunol. 2022. PMID: 35720400 Free PMC article.
Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
Faustini SE, Cook A, Hill H, Al-Taei S, Heaney J, Efstathiou E, Tanner C, Townsend N, Ahmed Z, Dinally M, Hoque M, Goodall M, Stamataki Z, Plant T, Chapple I, Cunningham AF; PITCH consortium; Drayson MT, Shields AM, Richter AG. Faustini SE, et al. Among authors: efstathiou e. J Infect. 2023 Oct;87(4):328-335. doi: 10.1016/j.jinf.2023.07.018. Epub 2023 Aug 3. J Infect. 2023. PMID: 37543310 Free article.
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.
Ranganathan S, Riveros C, Xu J, Hu S, Geng M, Huang E, Melchiode Z, Zhang J, Efstathiou E, Chan KS, Wallis CJD, Sonpavde G, Satkunasivam R. Ranganathan S, et al. Among authors: efstathiou e. Urol Oncol. 2024 May 18:S1078-1439(24)00428-9. doi: 10.1016/j.urolonc.2024.04.006. Online ahead of print. Urol Oncol. 2024. PMID: 38763801
Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents.
Efstathiou E, Merseburger A, Liew A, Kurtyka K, Panda O, Dalechek D, Heerdegen ACS, Jain R, De Solda F, McCarthy SA, Brookman-May SD, Mundle SD, Yu Ko W, Krabbe LM. Efstathiou E, et al. ESMO Open. 2024 May 13;9(5):103007. doi: 10.1016/j.esmoop.2024.103007. Online ahead of print. ESMO Open. 2024. PMID: 38744101 Free article.
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.
Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Gentile E, et al. Among authors: efstathiou e. Cancer Res Commun. 2023 Dec 13;3(12):2531-2543. doi: 10.1158/2767-9764.CRC-23-0362. Cancer Res Commun. 2023. PMID: 37930121 Free PMC article.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, Giorgi U, Shore ND, Saad F. Hussain M, et al. Among authors: efstathiou e. Future Oncol. 2023 Sep;19(29):1953-1960. doi: 10.2217/fon-2023-0135. Epub 2023 Aug 10. Future Oncol. 2023. PMID: 37585665 Free article. Review.
227 results